This study tests an experimental drug called AR1001 in people with early Alzheimer's disease. About 1,535 participants will receive either the drug or a placebo for 52 weeks to see if it slows down memory and thinking decline. The goal is to find a treatment that helps control th…
Phase: PHASE3 • Sponsor: AriBio Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 09:50 UTC